Alpaslan TANOĞLU, Ergenekon KARAGÖZ, Asım ÜLÇAY, Vedat TURHAN, Muammer KARA, YUSUF YAZGAN

Kronik Hepatit B Hastalarında Karaciğer Fibrozisinin Ciddiyetinin Belirlenmesinde Nötrofil/Lenfosit Oranı ve Ortalama Trombosit Hacminin Klinik Önemi

Bu çalışmada; kronik hepatit B hastalarında nötrofil/lenfosit oranı (NLO), ortalama trombosit hacmi (OTH) ve diğer biyokimyasal parametrelerin karaciğer fibrozisinin ciddiyetini belirlemedeki klinik önemini değerlendirmeyi amaçladık. Karaciğer biyopsisi uygulanmış toplam 95 naif KHB hastası çalışmaya dahil edildi. Lökosit, trombosit, hemoglobin sayımı, nötrofil, lenfosit, OTH ve diğer rutin biyokimyasal parametreler test edildi. Ishak skorlama sistemine göre karaciğer biyopsi örnekleri incelendi. Fibrozis derecesi 0, 1 ve 2 olanlar Grup 1, fibrozis düzeyi 3 ve üzeri olanlar Grup 2 olarak belirlendi. Mevcut verilerimizin analizleri SPSS 15 programı ile gerçekleştirildi. 'p' değerinin

Clinical Significance of Neutrophil to Lymphocyte Ratio and Mean Platelet Volume for Predicting the Severity of Hepatic Fibrosis in Patients with Chronic Hepatitis B

In this study, we aimed to determine the clinical significance of the neutrophil to lymphocyte (NLR) ratio, mean platelet volume (MPV) and other biochemical parameters for predicting the degree of liver fibrosis in patients with chronic hepatitis B (CHB) infection. A total of 95 biopsy-proven naïve CHB cases patients were included in the study. The complete blood count variables including white blood cell, hemoglobin, hematocrit, platelet count, neutrophil, lymphocyte, MPV, and other routine biochemical parameters were tested. Liver biopsy samples were examined using the Ishak scoring system. Individuals with a fibrosis score of 0, 1 and 2 were included in Group 1 and 3,4,5 and 6 were included in Group 2. Data analyses were carried out using SPSS 15 software. Statistical significance was set at a p-value of less than 0.05.Of the 95 cases, 76 (80%) were men and 19 (20%) were women. The mean age of the patients was 39.91±18.6 years, and 30 cases (31.5%) had HBeAg positivity. Fibrosis scores of 36 cases (37.8%) were greater than or equal to 3, whereas 59 cases (62.2%) had fibrosis scores less than 3. There was a significant difference between these two groups for NLR (Group 1; 2.38± 0.96, Group 2; 1.64 ± 0.60, p

PDF

___

1. Block TM, Rawat S, Brosgart CL. Chronic hepatitis B: A wave of new therapies on the horizon. Antiviral Res. 2015;121:69-81.
2. Tawada A, Kanda T, Yokosuka O. Current and future directions for treating hepatitis B virus infection. World J Hepatol. 2015;7(11):1541-52.
3. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335-52.
4. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S; Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2(3):263-83.
5. Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. Fibroindex: a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology. 2007;45(2):297-306.
6. Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, MacQuillan G, Speers D, Jeffrey G. Validation of the fibrotest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem. 2003;49(3):450-4.
7. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, Farrell G, McCaughan GW, Jeffrey GP. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51(10):1867-73.
8. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-26.
9. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011;17(1):47-58.
10. Beyan C. Is mean platelet volume a predictive marker in patients with venous thrombosis? Clin Appl Thromb Hemost. 2012;18(6):670-1.
11. Hendra TJ, Oswald GA, Yudkin JS. Increased mean platelet volume after acute myocardial infarction relates to diabetes and to cardiac failure. Diabetes Research and Clinical Practice. 1988;5(1):63-9.
12. Lancé MD, Sloep M, Henskens YM, Marcus MA. Mean platelet volume as a diagnostic marker for cardiovascular disease: drawbacks of preanalytical conditions and measuring techniques. Clin Appl Thromb Hemost. 2012;18(6):561-8.
13. Alkhouri N, Tamimi TA, Yerian L, Lopez R, Zein NN, Feldstein AE. The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Dig Dis Sci. 2010;55(9):2644-50.
14. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008;102(6):653-7.
15. Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A, Prasad KR, Toogood GJ, Lodge JP. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol. 2008;34(1):55-60.
16. Schinzari V, Barnaba V, Piconese S. Chronic HBV and HCV infections and cancer: synergy between viral and host factors. Clin Microbiol Infect. 2015 Jul 7. pii: S1198- 743X(15)00688-6. doi: 10.1016/j.cmi.2015.06.026. [Epub ahead of print]
17. Elbahrawy A, Alaboudy A, El Moghazy W, Elwassief A, Alashker A, Abdallah AM. Occult hepatitis B virus infection in Egypt. World J Hepatol. 2015;7(12):1671-8.
18. Ceylan B, Mete B, Fincanci M, Aslan T, Akkoyunlu Y, Ozguneş N, Colak O, Gunduz A, Senates E, Ozaras R, Inci A, Tabak F. A new model using platelet indices to predict liver fibrosis in patients with chronic hepatitis B infection. Wien Klin Wochenschr. 2013;125(15-16):453-60.
19. Enomoto H, Bando Y, Nakamura H, Nishiguchi S, Koga M. Liver fibrosis markers of nonalcoholic steatohepatitis. World J Gastroenterol. 2015;21(24):7427-35.
20. Enomoto M, Morikawa H, Tamori A, Kawada N. Noninvasive assessment of liver fibrosis in patients with chronic hepatitis B. World J Gastroenterol. 2014;20(34):12031-8.
21. Azab B, Jaglall N, Atallah JP, Lamet A, Raja-Surya V, Farah B, Lesser M, Widmann WD. Neutrophil-lymphocyte ratio as a predictor of adverse outcomes of acute pancreatitis. Pancreatology. 2011;11(4):445-52.
22. Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, Widmann WD. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012;19(1):217-24.
23. Cedrés S, Torrejon D, Martínez A, Martinez P, Navarro A, Zamora E, Mulet-Margalef N, Felip E. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol. 2012;14(11):864-9.
24. Alkhouri N, Morris-Stiff G, Campbell C, Lopez R, Tamimi TA, Yerian L, Zein NN, Feldstein AE. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2012;32(2):297-302.
25. Celikbilek M, Dogan S, Gursoy S, Zararsız G, Yurci A, Ozbakır O, Guven K, Yucesoy M. Noninvasive assessment of liver damage in chronic hepatitis B. World J Hepatol. 2013;5(8):439-45.
26. Yilmaz B, Aydin H, Can G, Şentürk Z, Üstüner B, Yilmaz H, Öztürkler M, Roach EC, Korkmaz U, Kurt M, Çelebi A, Şentürk Ö, Hülagü S. The relationship between fibrosis level and blood neutrophil to lymphocyte ratio in inactive hepatitis B carriers. Eur J Gastroenterol Hepatol. 2014;26(12):1325-8.
27. Purnak T, Olmez S, Torun S, Efe C, Sayilir A, Ozaslan E, Tenlik I, Kalkan IH, Beyazit Y, Yuksel O. Mean platelet volume is increased in chronic hepatitis C patients with advanced fibrosis. Clin Res Hepatol Gastroenterol. 2013;37(1):41-6.
28. Ekiz F, Yüksel O, Koçak E, Yılmaz B, Altınbaş A, Çoban S, Yüksel I, Üsküdar O, Köklü S. Mean platelet volume as a fibrosis marker in patients with chronic hepatitis B. J Clin Lab Anal. 2011;25(3):162-5.
29. Hu Y, Lou Y, Chen Y, Mao W. Evaluation of mean platelet volume in patients with hepatitis B virus infection. Int J Clin Exp Med. 2014;7(11):4207-13.
30. Inci A, Erus S. Mean Platelet Volume in Patients with Chronic Hepatititis B. J Clin Anal Med. 2015;6(4):458-60.
31. Liu WP, Xu DJ, Zhao LR, Lu ZH, Wang YH, Lang ZW, Wang GQ. The prediction and validation of liver fibrosis by a noninvasive model and validation in patients with chronic hepatitis B. Zhonghua Neike Zazhi. 2008;47(4):308-12.
32. Zhou K, Gao CF, Zhao YP, Liu HL, Zheng RD, Xian JC, Xu HT, Mao YM, Zeng MD, Lu LG. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2010; 25(9):1569-77.
33. Wu SD, Ni YJ, Liu LL, Li H, Lu LG, Wang JY. Establishment and validation of a simple noninvasive model to predict significant liver fibrosis in patients with chronic hepatitis B. Hepatol Int. 2012;6(1):360-8.